EMD-47357

Single-particle
2.12 Å
EMD-47357
3D View Gallery
Deposition: 18/10/2024
Map released: 30/10/2024
Last modified: 25/06/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-47357

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

Structure of RyR1 in the primed state in the presence of caffeine - focused map (reprocessed from EMPIAR-10997)

EMD-47357

Single-particle
2.12 Å
EMD-47357
3D View Gallery
Deposition: 18/10/2024
Map released: 30/10/2024
Last modified: 25/06/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Oryctolagus cuniculus
Sample: RyR1 in complex with calstabin-1 and calmodulin

Deposition Authors: Miotto MC , Marks AR
Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders.
Miotto MC , Luna-Figueroa E, Tchagou C, Bahlouli L, Reiken S , Dridi H, Liu Y , Weninger G , Marks AR
(2025) PNAS , 122 , e2422082122 - e2422082122
PUBMED: 40512792
DOI: doi:10.1073/pnas.2422082122
ISSN: 1091-6490
ASTM: PNASA6
Grant Support: